Calyxo, Inc.
$2.7M 1,299 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Galvanize Therapeutics, Inc
Galvanize Therapeutics, Inc reported $2,674,389.15 across General Payments, Research, and Ownership to 830 physicians and teaching hospitals across 956 transactions.
- $2.7M
- All-tracks total
- 956
- Transactions
- 830
- Recipients
- +$130.7K
- General Payments vs PY2023
Galvanize Therapeutics, Inc reported $2,674,389.15 across all CMS Open Payments tracks (General + Research + Ownership) to 830 physicians and teaching hospitals in Program Year 2024 - ranking #390 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $228,170.34, averaging $3.2K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer galvanize-therapeutics-inc Galvanize Therapeutics, Inc
$2.7M · #390/1,925 · 0.0% industry · PY2024
- TOT $2.7M
- RANK #390
- SHARE 0.0%
- TXN 956
- RCP 830
- CAT 4
- GEN $228.2K
- ΔGEN +$130.7K
- TOP1 26.2%
- PY 2024
Volume peers
Nearest volume peer: Calyxo, Inc. ($2.7M)
Galvanize Therapeutics, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Galvanize Therapeutics, Inc's CMS-reported General Payments increased by $130.7K (+134.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GALVANIZE THERAPEUTICS, INCPY2023: GALVANIZE THERAPEUTICS, INCPY2024: Galvanize Therapeutics, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $97,478.51
- PY2024
- $228,170.34
What the Data Shows for Galvanize Therapeutics, Inc
Rank #390 of 1,925 companies in CMS Open Payments for 2024 belongs to Galvanize Therapeutics, Inc, which reported $2,674,389.15 across 956 transactions to 830 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $2.8K per transaction and $3.2K per recipient.
Of the 4 general-payment categories charted below, "Consulting Fee" is the largest at $151.0K across 39 transactions, 66.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Galvanize Therapeutics, Inc made 4 types of general payments. "Consulting Fee" is the largest category at $151.0K, 66.2% of General Payments.
Galvanize Therapeutics, Inc reports 4 general-payment categories - the top three are Consulting Fee (66.2%), Food and Beverage (29.6%), and Travel and Lodging (3.8%). The remaining 1 category make up 0.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Galvanize Therapeutics, Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $151.0K | 39 | 66.2% |
| Food and Beverage | $67.5K | 763 | 29.6% |
| Travel and Lodging | $8.7K | 20 | 3.8% |
| Entertainment | $1.0K | 8 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $139,288.33 (61.0%) of $228,170.34 in this company's General Payments records across 556 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Galvanize Therapeutics, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Joseph Mammarappallil
$59,716.65 across 60 reported transactions
- 2
William Moore
$33,272.01 across 14 reported transactions
- 3
Robert Suh
$19,308.93 across 4 reported transactions
- 4
Michael Pritchett
$18,404.43 across 8 reported transactions
- 5
Joseph Whitlark
$8,586.31 across 10 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Galvanize Therapeutics, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Galvanize Therapeutics, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Galvanize Therapeutics, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
CVRx, Inc.
$2.7M 16,025 recipients
Compare payment profiles
Vertical Orthopaedics, Inc.
$2.7M 19 recipients
Compare payment profiles
Global Blood Therapeutics, Inc.
$2.7M 0 recipients
Compare payment profiles
Nanovis LLC
$2.7M 24 recipients
Compare payment profiles
Ardelyx, Inc.
$2.6M 42,247 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.